The HEMEMICS platform empowers healthcare providers to rapidly identify pathogens.
Our novel multiplexed immuno-biosensor could provide rapid detection of COVID-19 anywhere in the world.
Rapid, cost-effective and real-time biomarker measurements are essential for quick and effective diagnosis and treatment of emerging diseases like COVID-19.
HEMEMICS has developed a diagnostic test platform that can yield sensitive, selective, and measurable signals with a single nasal swab or drop of blood. Testing is simple and could be administered by any health care worker, anywhere: ambulances, emergency rooms, community clinics and makeshift hospitals.
Most importantly, this Bluetooth® connected technology transmits the test results to a cloud-based data management network, enabling real-time geographical alerts of outbreaks or travel screening at airports, borders and transportation terminals.
HEMEMICS awarded a CRADA (co-operative research and development agreement) with the U.S. Army
HEMEMICS is working with the U.S. Army in the development of a portable bio-defense platform.
Better understand the immune response and transmission dynamics of the SARS CoV-2 virus
Improve diagnostic testing for COVID-19, the disease caused by the virus
HEMEMICS is aggressively responding to this need with faster testing technology to address this public health emergency. This easy-to-use and easy-to-read diagnostic device can quickly identify an array of telltale proteins for pathogen detection.
A Significant Advantage for Clinicians and Healthcare Workers
The proprietary HEMEMICS Biosensor system can simultaneously test for up to 31 different pathogens using a single drop of sample. The handheld reader and test chips are small enough to be easily carried in a pocket, allowing POC diagnosis anywhere.
Real-time virus detection and outbreak mapping with the HEMEMICS platform could spell the difference between accelerating or blunting the spread of an epidemic.
How HEMEMICS’ Technology Is Changing Healthcare
Patented Preservative Makes the HEMEMICS “ChipLab” Possible
Our patented HEMSOL™ solution preserves detecting biology anchored to carbon-based sensors.
This extends shelf life of the antibodies on the chip – NO refrigeration is needed.
HEMEMICS’ proprietary platform – protected by 3 issued patents – liberates diagnostic testing from the central lab. This makes it possible and cost-effective to perform tests at the bedside or in the field for nearly instant answers.
To find out more about how the HEMEMICS technology can uniquely address COVID-19 and other diagnostic challenges, contact us.